1. Volume 70, Issue 4, Pages 668-674 (October 2016)
Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort 
Louise Dickinson, Manit Arya, Naveed Afzal, Paul Cathcart, Susan C. Charman, Andrew Cornaby, Richard G. Hindley, Henry Lewi, Neil McCartan, Caroline M. Moore, Senthil Nathan, Chris Ogden, Raj Persad, Jan van der Meulen, Shraddha Weir, Mark Emberton, Hashim U. Ahmed 
European Urology 
Volume 70, Issue 4, Pages (October 2016)
DOI: /j.eururo
Copyright © Terms and Conditions

2. Fig. 1
Kaplan-Meier curves demonstrating (A) primary composite disease control in men undergoing whole-gland high-intensity focused ultrasound (HIFU) for prostate cancer in the UK. No transition to any of local salvage therapy (surgery or radiotherapy), systemic therapy, metastases or prostate cancer-specific mortality. (B) Kaplan-Meier curves demonstrating primary composite disease control by National Comprehensive Cancer Network risk groups in men undergoing whole-gland HIFU for prostate cancer in the UK (defined as no transition to any of local salvage therapy [surgery or radiotherapy], systemic therapy, metastases, or prostate cancer-specific mortality).
CI=confidence interval.
European Urology  , DOI: ( /j.eururo )
Copyright © Terms and Conditions

3. Fig. 2
Kaplan-Meier curves demonstrating (A) overall biochemical disease-free survival (Stuttgart criteria) in men undergoing whole-gland high-intensity focused ultrasound (HIFU) for prostate cancer in the UK and (B) demonstrating biochemical disease-free survival (Stuttgart criteria) by National Comprehensive Cancer Network risk group in men undergoing whole-gland HIFU for prostate cancer in the UK.
CI=confidence interval.
European Urology  , DOI: ( /j.eururo )
Copyright © Terms and Conditions

4. Fig. 3
Kaplan-Meier curves demonstrating (A) overall biochemical disease-free survival (Phoenix criteria) in men undergoing whole-gland high-intensity focused ultrasound (HIFU) for prostate cancer in the UK and (B) demonstrating biochemical disease-free survival (Phoenix criteria) by National Comprehensive Cancer Network risk group in men undergoing whole-gland HIFU for prostate cancer in the UK.
CI=confidence interval.
European Urology  , DOI: ( /j.eururo )
Copyright © Terms and Conditions